A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir

Journal of Virological Methods

Volumn 193, Issue 1, 2013, Pages 68-76

  O'Boyle, Donald R ^a   Nower, Peter T ^a   Sun, Jin Hua ^a   Fridell, Robert ^a   Wang, Chunfu ^a   Valera, Lourdes ^a   Gao, Min ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

BMS 790052; DAA; Daclatasvir; HCV resistance barrier; Luciferase assay

Indexed keywords

DACLATASVIR; LUCIFERASE; NONSTRUCTURAL PROTEIN 5A;

AMPLICON; ARTICLE; CELL DENSITY; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REPLICON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN;

BMS-790052; DAA; DACLATASVIR; HCV RESISTANCE BARRIER; LUCIFERASE ASSAY;

ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HUMANS; IMIDAZOLES; LUCIFERASES; MICROBIAL SENSITIVITY TESTS; STAINING AND LABELING; VIROLOGY; VIRUS REPLICATION;

DROSOPHILA C VIRUS; HEPATITIS C VIRUS;

EID: 84879156452     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2013.04.024     Document Type: Article

References (25)

1. Blight K.J., Kolykhalov A.A., Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290:1972-1974.
2. Chayama K., Takahashi S., Toyota J., Karino Y., Ikeda K., Ishikawa H., Watanabe H., McPhee F., Hughes E., Kumada H. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012, 55:742-748.
3. Choi J., Lee K.J., Zheng Y., Yamaga A.K., Lai M.M.C., Ou J.H. Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. Hepatology 2004, 3981-3989.
4. Fanning L.J. Practical consequences of hepatitis C virus quasispecies for target-specific antivirals. J. Infect. Dis. 2008, 198:797-799.
5. Friborg J., Levine S., Chen C., Sheaffer A.K., Chaniewski S., McPhee F. Combinations of interferon lambda with direct-acting antiviral agents are highly efficient in suppressing Hepatitis C virus replication. Antimicrob. Agents Chemother. 2013, 57:1312-1322.
6. Fridell R.A., Qiu D., Wang C., Valera L., Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 2010, 54:3641-3650.
7. Fridell R.A., Qiu D., Valera L., Wang C., Rose R.E., Gao M. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J. Virol. 2011, 85:7312-7320.
8. Gao M., Nettles R.E., Belema M., Snyder L.B., Nguyen V.N., Fridell R.A., Serrano-Wu M.H., Langley D.R., Sun J.H., O'Boyle D.R., Lemm J.A., Wang C., Knipe J.O., Chien C., Colonno R.J., Grasela D.M., Meanwell N.A., Hamann L.G. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010, 465:96-100.
9. Gao M., Fridell R.A., Wang C., Sun J.-H., O'Boyle D.R., Valera L., Nower P.T., Monikowski A., Kirk M., Huang H., Ngo C., Fang H., Knox R., Wang Y.-K., Nguyen V., Wang F., Snyder L., Lavoie R., Bender J., Kadow J., Cockett M., Meanwell N.A., Belema M. BMS-766, a novel HCV NS5A inhibitor with enhanced resistance coverage. EASL Poster, 2011 2011.
10. Hao W., Herlihy K.J., Zhang N.J., Fuhrman S.A., Doan C., Patick A.K., Duggal R. Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening. Antimicrob. Agents Chemother. 2007, 51:95-102.
11. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., Marcellin P., Muir A.J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R.A., Yoshida E.M., Adda N., Bengtsson L., Sankoh A.J., Kieffer T.L., George S., Kauffman R.S., Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011, 364:2405-2416.
12. Kwo P.Y., Lawitz E.J., McCone J., Schiff E.R., Vierling J.M., Pound D., Davis M.N., Galati J.S., Gordon S.C., Ravendhran N., Rossaro L., Anderson F.H., Jacobson I.M., Rubin R., Koury K., Pedicone L.D., Brass C.A., Chaudhri E., Albrecht J.K. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
13. Delang L., Vliegen I., Leyssen P., Neyts J. In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors. J. Hepatol. 2012, 56:41-48.
14. Lok A.S., Gardiner D.F., Lawitz E., Martorell C., Everson G.T., Ghalib R., Reindollar R., Rustgi V., McPhee F., Wind-Rotolo M., Persson A., Zhu K., Dimitrova D.I., Eley T., Guo T., Grasela D.M., Pasquinelli C. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 2012, 366:216-224.
15. McCown M.F., Rajyaguru S., Le Pogam S., Ali S., Jiang W.R., Kang H., Symons J., Cammack N., Najera I. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 2008, 52:1604-1612.
16. O'Boyle D.R., Nower P.T., Lemm J.A., Valera L., Sun J.-H., Rigat K., Colonno R., Gao M. Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrob. Agents Chemother. 2005, 49:1346-1353.
17. Pelosi L.A., Voss S., Liu M., Gao M., Lemm J.A. Effect on HCV replication by combinations of direct acting antivirals including NS5A inhibitor daclatasvir. Antimicrob. Agents Chemother. 2012, 56:5230-5239.
18. Qadri I., Iwahashi M., Capasso J.M., Hopken M.W., Flores S., Schaack J., Simon F.R. Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis C virus replication: role of JNK, p38 MAPK and AP-1. Biochem. J. 2004, 378:919-928.
19. Quinkert D., Bartenschlager R., Lohmann V. Quantitative analysis of the hepatitis C virus replication complex. J. Virol. 2005, 79:13594-13605.
20. Robinson M., Tian Y., Pagratis N., Delaney W.E. Screening of hepatitis C virus inhibitors using genotype 1a HCV replicon cell lines. Curr. Protoc. Microbiol. 2011, (Chapter 1, Unit 17.7).
21. Robinson M., Tian Y., Delaney W.E., Greenstein A.E. Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:10290-10295.
22. Scheel T.K., Gottwein J.M., Mikkelsen L.S., Jensen T.B., Bukh J. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an ns5a inhibitor but not interferon-α. Gastroenterology 2011, 140:1032-1042.
23. Shafer R.W., Vuitton D.A. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed. Pharmacother. 1999, 53:73-86.
24. Stuyver L.J., McBrayer T.R., Tharnish P.M., Hassan A.E., Chu C.K., Pankiewicz K.W., Watanabe K.A., Schinazi R.F., Otto M.J. Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. J. Virol. 2003, 77:10689-10694.
25. Wang C., Huang H., Valera L., Sun J.-H., O'Boyle D.R., Nower P.T., Jia L., Qiu D., Huang X., Altaf A., Gao M., Fridell R.A. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob. Agents Chemother. 2012, 56:1350-1358.